AUTH/3015/1/18: Daiichi-Sankyo voluntary admission—medical signatories acted before MHRA/PMCPA notification

📅 2018 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/3015/1/18
CompanyDaiichi-Sankyo UK Ltd
Case typeVoluntary admission (treated as a complaint under Paragraph 5.6 of the Constitution and Procedure)
IssueThree medical staff acted as nominated signatories before their names/qualifications were notified in advance to MHRA and PMCPA
Volume impacted296 items certified prior to notification
Applicable Code year2016
Breach clauses14.1; 14.4
Complaint received29 January 2018
Completed30 May 2018
AppealNo appeal
SanctionsUndertaking received

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • Daiichi-Sankyo UK discovered (and voluntarily admitted) that three medical staff acted as nominated signatories before their names and qualifications were notified in advance to the MHRA and the PMCPA.
  • The issue arose from an administrative error linked to staff departures and lack of handover; the SOP did not assign a specific role to make the external notifications.
  • The omission came to light during an investigation connected to an intercompany complaint about Lixiana (Case AUTH/3010/1/18) when signed certificates were requested.
  • The three medical signatories certified 296 items of material before notification was completed on 22 January 2018.
  • Daiichi-Sankyo informed the MHRA and PMCPA, submitted a voluntary admission, and initiated a CAPA plan including SOP updates and training.
⚖️

Outcome

  • The Panel ruled that Daiichi-Sankyo breached the Code.
  • Failure to notify signatories in advance was a breach of Clause 14.4.
  • As a consequence, the materials certified by those signatories prior to notification were not certified in accordance with the Code, breaching Clause 14.1.
  • No appeal.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training